Shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) have been given a consensus recommendation of “Buy” by the sixteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $29.23.

A number of analysts recently weighed in on ALDR shares. Credit Suisse Group set a $11.00 target price on shares of Alder BioPharmaceuticals and gave the stock a “hold” rating in a report on Thursday, August 24th. BidaskClub upgraded shares of Alder BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Mizuho started coverage on shares of Alder BioPharmaceuticals in a report on Wednesday, September 6th. They set a “buy” rating and a $32.00 target price for the company. Royal Bank Of Canada started coverage on shares of Alder BioPharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating and a $17.00 target price for the company. Finally, Cowen started coverage on shares of Alder BioPharmaceuticals in a report on Tuesday, September 26th. They set an “outperform” rating and a $20.00 target price for the company.

Alder BioPharmaceuticals (ALDR) traded down $0.25 during midday trading on Monday, hitting $10.70. 521,777 shares of the company were exchanged, compared to its average volume of 1,112,190. Alder BioPharmaceuticals has a fifty-two week low of $8.60 and a fifty-two week high of $25.45.

Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.21) by $0.29. During the same quarter last year, the business posted ($0.70) EPS. research analysts expect that Alder BioPharmaceuticals will post -5.14 EPS for the current fiscal year.

In related news, insider Mark James Litton sold 16,519 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $10.80, for a total value of $178,405.20. Following the completion of the transaction, the insider now owns 116,451 shares of the company’s stock, valued at approximately $1,257,670.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 10.60% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in shares of Alder BioPharmaceuticals by 5.5% during the 2nd quarter. Vanguard Group Inc. now owns 3,626,573 shares of the biopharmaceutical company’s stock valued at $41,525,000 after buying an additional 187,871 shares during the period. Janus Henderson Group PLC acquired a new stake in shares of Alder BioPharmaceuticals during the 2nd quarter valued at $36,956,000. Redmile Group LLC boosted its stake in shares of Alder BioPharmaceuticals by 16.4% during the 2nd quarter. Redmile Group LLC now owns 2,223,811 shares of the biopharmaceutical company’s stock valued at $25,463,000 after buying an additional 313,925 shares during the period. State Street Corp boosted its stake in shares of Alder BioPharmaceuticals by 9.4% during the 2nd quarter. State Street Corp now owns 1,944,755 shares of the biopharmaceutical company’s stock valued at $22,267,000 after buying an additional 167,642 shares during the period. Finally, BB Biotech AG boosted its stake in shares of Alder BioPharmaceuticals by 15.2% during the 2nd quarter. BB Biotech AG now owns 1,941,008 shares of the biopharmaceutical company’s stock valued at $22,225,000 after buying an additional 255,858 shares during the period. 96.88% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Alder BioPharmaceuticals, Inc. (ALDR) Given Average Rating of “Buy” by Analysts” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/11/alder-biopharmaceuticals-inc-aldr-given-average-rating-of-buy-by-analysts.html.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Analyst Recommendations for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.